Polyester Nanoparticles Target Brain Endothelium Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for traumatic brain injury (TBI) are limited, primarily focusing on symptom management rather than targeted repair of the injured brain endothelium, and there is a need for theragnostic approaches that can specifically diagnose and treat the injured endothelium.
Innovation Solution
Engineered polymeric nanoparticles, such as those derived from polylactic acid (PLA) or poly(lactic-co-glycolic acid) (PLGA), are used to encapsulate therapeutic agents like poloxamer 188 (P188) and N-acetylcysteine (NAC), which are decorated with targeting ligands to specifically bind to injured endothelial cells, allowing for targeted delivery across the blood-brain barrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pharmacological treatments are used for TBI, then symptom management is achieved, but targeted repair of injured brain endothelium is not possible
Solution Approach 1:
The patent uses engineered polymeric nanoparticles as intermediaries to deliver therapeutic agents specifically to injured brain endothelium. These nanoparticles are decorated with targeting ligands that recognize and bind to biomarkers on injured endothelial cells, enabling selective delivery of repair agents to the damaged tissue while leaving healthy tissue unaffected. This resolves the contradiction by providing both systematic symptom management and localized targeted repair through the nanoparticle mediator.
Solution Approach 2:
The patent implements local quality by concentrating therapeutic agents specifically at the site of endothelial injury through targeted nanoparticle delivery. The nanoparticles accumulate preferentially at injured sites where biomarkers are upregulated, delivering high concentrations of repair agents locally while maintaining low systemic concentrations. This enables targeted repair of injured brain endothelium without requiring non-specific pharmacological intervention throughout the entire body.
2Quantity of substance
If therapeutic agents are administered systemically, then broad coverage is achieved, but specific delivery to injured endothelium is compromised
Solution Approach 1:
The patent changes the physical and chemical parameters of the therapeutic delivery system by using nanoparticles with specific size ranges (20-200 nm), surface charges, and degradation rates. These parameter optimizations enable the nanoparticles to navigate the bloodstream effectively, cross the blood-brain barrier, and accumulate at injured sites through enhanced permeability and retention effects, thereby achieving both broad distribution and precise targeting.
Solution Approach 2:
The nanoparticles serve as intermediaries that carry therapeutic agents through the bloodstream to the brain, crossing the blood-brain barrier and accumulating at injured endothelial sites. The targeting ligands on the nanoparticle surface act as mediators that recognize specific biomarkers on injured cells, ensuring precise delivery while maintaining adequate systemic distribution for broad coverage.
3Ease of operation
If the blood-brain barrier is made more permeable to allow drug delivery, then therapeutic access is improved, but selective targeting of injured tissue is reduced
Solution Approach 1:
The patent uses targeting ligands on the nanoparticle surface as intermediaries that specifically recognize and bind to biomarkers upregulated on injured endothelial cells. This specific recognition enables the nanoparticles to distinguish between healthy and injured tissue, maintaining high tissue specificity even when the blood-brain barrier is compromised or when delivering through a more permeable barrier.
Solution Approach 2:
The patent achieves local quality by designing nanoparticles that preferentially accumulate at sites of endothelial injury through targeted binding to injury-specific biomarkers. Even when the blood-brain barrier allows broader penetration, the nanoparticles concentrate specifically at injured sites where the targeting ligands bind to their ligands, ensuring selective delivery to damaged tissue while minimizing off-target effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the targeted delivery of therapeutic agents to the injured brain endothelium, restoring structural and functional integrity, reducing oxidative stress, and improving permeability, thereby providing a potential theragnostic treatment for TBI.
Implementation Method 1
a targeting ligand bound to the nanoparticle, wherein the targeting ligand binds to a biomarker for the injured, inflamed, diseased, or disrupted endothelial cells
Implementation Method 2
Encapsulating the therapeutic agents in the biocompatible polyester derived nanoparticles, the therapeutic agents can be delivered to an injury site, for example in the brain, through orally administering the nanoparticles
Data Source
AI summary
Provided herein are compositions and methods for diagnosis and therapy through targeted nano-delivery to injured brain endothelium. In some aspects, the compositions comprise a population of polyester derived nanoparticles, wherein each polyester derived nanoparticle comprises a) a therapeutic agent encapsulated therein for treating traumatically injured, inflamed, diseased, or disrupted endothelial cells, and b) a targeting ligand bound to the nanoparticle, wherein the targeting ligand binds to a biomarker for the injured, inflamed, diseased, or disrupted endothelial cells, are provided. The nanoparticles can be used for targeting difficult-to-reach injury sites, including the blood brain barrier and brain tissue.